Abingworth Management, of London, appointed John Berriman partner and John Shields assistant director.
Active Pass Pharmaceuticals Inc., of Vancouver, British Columbia, appointed David MacDonald vice president, research and development.
Aerogen Inc., of Sunnyvale, Calif., appointed John Ross senior vice president of worldwide operations and promoted Robert Fishman to vice president of clinical operations.
Akorn Inc., of Buffalo Grove, Ill., appointed Jerry Ellis to its board.
AlleCure Corp., of Valencia, Calif., appointed Candice Byrne director of human resources.
Amarin Corp. plc, of London, named Donald Joseph executive vice president, legal and commercial development for Amarin Pharmaceuticals Inc. and also corporate vice president of Amarin Corp. Steve Guillen was named vice president, sales and marketing, for Amarin Pharmaceuticals Inc.
Antigenics Inc., of New York, elected Samuel Waksal to its board.
Avanir Pharmaceuticals Inc., of San Diego, elected Susan Golding, Charles Mathews and Harold Oberkfell to its board.
Crucell N.V., of Leiden, the Netherlands, appointed Jaap Goudsmit senior vice president, vaccine research.
DrugAbuse Sciences Inc., of Hayward, Calif., added John de Brun as senior vice president, operations.
EmerGen Inc., of Salt Lake City, appointed Michael Mayer vice president, corporate development.
Vical Inc., of San Diego, formed a scientific advisory board comprised of Thomas Caskey, Phyllis Gardner, Paul Offit, Eric Olson, Douglas Richman and George Sledge.